Based on current operating plans, and assuming full execution of the $125 million share repurchase plan, we expect our ...
A look at the biologics, gene therapies, and vaccines most likely to reshape care —and manufacturing—in the year ahead.
J.B. Maverick is an active trader, commodity futures broker, and stock market analyst 17+ years of experience, in addition to 10+ years of experience as a finance writer and book editor. Amy is an ACA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results